Organ-specific Responses to Atezolizumab Plus Bevacizumab in Advanced HCC

Sponsor
CHA University
Study ID
NCT04862949
Status
Completed

Conditions

  • Advanced Hepatocellular Carcinoma

Eligibility Criteria

Sex
ALL
Age
19 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Atezolizumab plus bevacizumab — DRUG
    Patients received combination therapy with atezolizumab (Tecentriq) and bevacizumab (Avastin) as first-line systemic treatment for advanced hepatocellular carcinoma.

Study Details

Hepatocellular carcinoma (HCC) is one of the most frequent causes of cancer-related deaths globally and in Korea. Many patients diagnosed at advanced stage, and systemic therapy is mainstay of treatment in patients with advanced HCC. However, immune-checkpoint inhibitor (ICI) monotherapy did not significantly improve overall survival in phase III studies. According to previous retrospective analyses, ICI treatment in advanced HCC showed different organ-specific responses. The intrahepatic HCC was the least responsive organ to ICI treatment. The failure of phase III trials of ICI monotherapy may have been attributed to different organ-specific response pattern of ICIs. Combination of atezolizumab plus bevacizumab is expected to overcome the immunosuppressive microenvironment of liver and may enhance intrahepatic response of ICI.

Key Dates

Start date
May 1, 2021
Status verified
Dec 2025
Primary completion
Dec 31, 2022
Completion
Mar 9, 2023

Study Design

Enrollment
131 participants (actual)

Arms

  • Arm: Atezolizumab plus bevacizumab
    Patients received combination therapy with atezolizumab and bevacizumab as first-line systemic treatment for advanced HCC.

Primary Outcome Measure

Percentage of Lesions With Organ-specific Response [ Time Frame: From treatment initiation until last follow-up (median 10.1 months) ]

Related coverage on Hipa.ai

Related Studies